carbidopa-levodopa

Although Impax Laboratories Inc (NASDAQ: IPXL)'s prospects have improved since the remediation of its manufacturing issues in 2015, Goldman Sachs’ Stephan Stewart believes “the fundamental outlook is fully reflected in the stock,” and there could be “increased competition...